Current Research Studies
GATEWAY: Safety Evaluation of the MiniMed NMX8-AID System in Children and Adults Living with Diabetes
Medtronic CIP 351
What is the goal of the study?
This study is a multi-center, single-arm pivotal study in adult and pediatric subjects with T1D, as well as in insulin-requiring adults with T2D, using the NMX8 system with Simplera Sync. Baseline period and study period combined are approximately 142 days long for each subject. The period from Visit 1 (consent and screening) through Visit 3 (end of Baseline period) must be completed within 40 days. The study period (Visit 4-12) is approximately 102 days long. The study is anticipated to last approximately 16 - 20 months from first investigational center initiation to study completion (last subject, last visit completed).
Who can participate in the study?
Please contact the study team listed below to learn more.